A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
Overview
- Phase
- Not Applicable
- Intervention
- Bimatoprost Ophthalmic Solution
- Conditions
- Glaucoma, Primary Open Angle
- Sponsor
- Allergan
- Enrollment
- 1830
- Primary Endpoint
- IOP in the Study Eye at Week 12
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice. All treatment decisions lie with the physician.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosed with primary open-angle glaucoma or ocular hypertension
- •Previously prescribed intraocular pressure (IOP)-lowering medication with insufficient IOP control and is now being switched to Lumigan® UD for medical reasons
Exclusion Criteria
- Not provided
Arms & Interventions
Patients with POAG or OHT
Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
Intervention: Bimatoprost Ophthalmic Solution
Outcomes
Primary Outcomes
IOP in the Study Eye at Week 12
Time Frame: Week 12
IOP is a measurement of the fluid pressure inside the study eye.
Intraocular Pressure (IOP) in the Study Eye at Baseline
Time Frame: Baseline
IOP is a measurement of the fluid pressure inside the study eye.
Secondary Outcomes
- Number of Patients Who Discontinue Treatment With Lumigan® UD Prior to 12 Weeks of Treatment(12 Weeks)
- Physician Assessment of Tolerability on a 4-Point Scale(12 Weeks)
- Physician Assessment of IOP-Lowering Effect in the Study Eye on a 3-Point Scale(Baseline, 12 Weeks)
- Physician Assessment of Patient Compliance Compared to Previous Treatment on a 3-Point Scale(12 Weeks)
- Patient Assessment of Tolerability on a 4-Point Scale(12 Weeks)
- Number of Patients Who Continue Treatment(12 Weeks)